Literature DB >> 330775

Cross-reactive antigens: their potential for immunization-induced immunity to Gram-negative bacteria.

W R McCabe, S C Bruins, D E Craven, M Johns.   

Abstract

The involvement of multiple species and serologic types in gram-negative bacteremia prompted evaluation of immunization with shared, cross-reactive antigens of gram negative bacilli. Active and passive immunization with Re chemotype mutants of Salmonella minnesota afforded significant protection against heterologous gram-negative bacilli and were considerably more effective than immunization with smooth S. minnesota or its Ra, Rb, Rc, Rd1 and Rd2 mutants. Since the lipopolysaccharide of the Re mutant is composed solely of 2-keto-3-deoxycotonate (KDO) and lipid A, the protective activity of antibody to the Re mutant and lipid A was evaluated. Immunization with Re mutant protected granulocytopenic rabbits against lethal bacteremia and protected mice against lethal challenge with heterologous endotoxins, whereas antibody to lipid A had no protective activity. In concomitant clinical studies, high titers of antibody to the Re mutant at the onset of bacteremia were associated with a significant diminution in the frequency of shock and death, which was independent of any effect of O-specific antibody.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330775     DOI: 10.1093/infdis/136.supplement.s161

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis.

Authors:  Catherine H Valentine; Judith Hellman; Laura K Beasley-Topliffe; Aranya Bagchi; H Shaw Warren
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 3.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 4.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

5.  Inhibition of lipopolysaccharide mitogenicity with characterized anti-lipid A monoclonal antibodies.

Authors:  R Girard; R Chaby
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

6.  Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corrodens LPS.

Authors:  T Kato; I Takazoe; K Okuda
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

7.  Immunization against bacteria- and endotoxin-induced hypotension.

Authors:  A M Abdelnoor; A G Johnson; A Anderson-Imbert; A Nowotny
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

8.  Lipid A and anti-lipid A.

Authors:  I Mattsby-Baltzer; B Kaijser
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

9.  Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity.

Authors:  W C Bogard; D L Dunn; K Abernethy; C Kilgarriff; P C Kung
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

10.  Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.

Authors:  B J Appelmelk; A M Verwey-van Vught; J J Maaskant; W F Schouten; L G Thijs; D M Maclaren
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.